Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.
Sign In
New to ϳԹ?
Register for an account to quickly and easily purchase products online and for one-click access to all educational content.
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to ϳԹ Canada Inc. and its subsidiaries and affiliates (“ϳԹ”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
The OKT3 antibody reacts with an extracellular conformational epitope on the ~20 kDa CD3ε subunit of the human T cell receptor (TCR)/CD3 complex, which is expressed on the surface of ~95% of mature T cells and NKT cells, and variably on thymocytes. A majority of T cell neoplasms also express CD3. CD3 is a dimer assembled from combinations of CD3γ, δ, ε, η, and ζ subunits, which are structurally related type 1 transmembrane proteins and members of the immunoglobulin superfamily. CD3 associates non-covalently with the TCR and is involved in transducing antigen recognition signals into the cytoplasm of T cells and in regulating T cell activation and the expression of the TCR on the cell surface. Mutations in CD3 have been associated with disorders of the immune system, including severe combined immunodeficiency (SCID). The OKT3 antibody recognizes an epitope that is expressed when the CD3ε subunit associates with either CD3γ or CD3δ, and binding of the antibody can induce T cell activation. Because of its immunosuppressive properties in vivo, the OKT3 antibody has proven useful in treating allograft rejection. Clone OKT3 is widely used for phenotyping human T cells, and it has been observed to block the binding of anti-CD3 antibody clones SK7 and UCHT1.
Subtype
Primary Antibodies
Target Antigen
CD3
Alternative Names
CD3 epsilon, CD3ε, Leu-4, T3
Reactive Species
Human
Conjugation
APC, FITC, Unconjugated
Host Species
Mouse
Cell Type
T Cells
Application
Flow Cytometry, Functional Assay, Immunohistochemistry, Western Blotting
Figure 1. Data for Anti-Human CD3 Antibody, Clone OKT3, APC
Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD3 Antibody, Clone OKT3, APC (filled histogram) or a mouse IgG2a, kappa APC isotype control antibody (solid line histogram). Viable lymphocytes were gated for analysis.
Figure 2. Data for Anti-Human CD3 Antibody, Clone OKT3, FITC
Flow cytometry analysis of human PBMCs labeled with Anti-Human CD3 Antibody, Clone OKT3, FITC (filled histogram) or a mouse IgG2a, kappa FITC isotype control antibody (solid line histogram). Viable lymphocytes were gated for analysis.
Figure 3. Data for Anti-Human CD3 Antibody, Clone OKT3, Unconjugated
Flow cytometry analysis of human PBMCs labeled with Anti-Human CD3 Antibody, Clone OKT3, followed by a goat anti-mouse IgG2a antibody, PE (filled histogram) or a mouse IgG2a, kappa isotype control antibody, followed by a goat anti-mouse IgG2a antibody, PE (solid line histogram). Viable lymphocytes were gated for analysis.
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
Mouse monoclonal IgG2a, kappa isotype control antibody
Item added to your cart
Anti-Human CD3 Antibody, Clone OKT3, FITC
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ϳԹ, REFER TO WWW.ϳԹ.COM/COMPLIANCE.
